Digitisation | December 08, 2021
Olympus lays out its plans for growth in the medical business
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It is an extension of GE Healthcare’s online service delivery enterprise Service Shop
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
The fund aims at investing in companies that extends human healthspan
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Subscribe To Our Newsletter & Stay Updated
